CFL1 and neoplasm: In this work, considering the high concentration of GSH in tumor cells[34, 35] and the lack of clinically used inhibitors for CFL1, we therefore used the reduction‐responsive NPs for systemic co‐delivery of sorafenib and siRNA targeting CFL1 and evaluated their clinical translation potential for HCC therapy.